Overview
Sienna is the developer of a new diagnostic technology with potential utility in numerous cancer indications. It is the first company to develop an In-Vitro Diagnostic product (IVD) for the detection of hTERT, a component of telomerase, in human clinical samples.
Sienna has registered its product as a Class 1 IVD in the USA, a CE marked / General Class IVD in the EU, and a Class 2 IVD in Australia for clinical diagnostic use.
To view Presentation please download PDF attached:
Download this document
